NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
IPO Year: 2015
Exchange: NASDAQ
Website: novocure.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2025 | $14.50 | Overweight → Equal Weight | Wells Fargo |
| 7/8/2025 | $30.00 | Buy | Ladenburg Thalmann |
| 12/2/2024 | $18.00 → $30.00 | In-line → Outperform | Evercore ISI |
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2023 | $15.00 | Neutral | JP Morgan |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
| 8/4/2023 | $51.00 | Outperform | SVB Securities |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
| 6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
Fastest customizable press release news feed in the world
Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "With the first half of 2025 complete, I am pleased
TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly delayed the need for opioid pain medication for patients with unresectable, locally advanced pancreatic adenocarcinoma A significant delay in deterioration across measures of health status was observed, preserving quality of life longer in patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel These data complement the previously reported overall survival benefit seen in PANOVA-3, supporting TTFields concomitant with gemcitabine and nab-paclitax
Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.co
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) announced that results from the Phase 3 PANOVA-3 tr
Novocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial, to review the results and address questions. To request in-person attendance, please contact investor relations at [email protected]. Jefferies Global Healthcare Conference, June 4, 2025: Ashley Cordova, Chi
Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen Novocure (NASDAQ:NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive for
Novocure (NASDAQ:NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The company previously announced positive topline results from PANOVA-3 that demonstrated the trial met its primary endpoint, achieving a statistically significant improvement in median overall survival in p
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark approval is supported by the Phase 3 LUNAR trial, which demonstrated the first substantial improvement in median overall survival in more than 8 years for this patient population Optune Lua is a wearable medical device that delivers Tumor Treating Fields (TTFields), a first-of-its-kind therapy for metastatic NSCLC that uses electric fields to kill cancer cells Novocure (NASDAQ:NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult pat
Novocure (NASDAQ:NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/investor-
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - NovoCure Ltd (0001645113) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
SCHEDULE 13G - NovoCure Ltd (0001645113) (Subject)
8-K - NovoCure Ltd (0001645113) (Filer)
10-Q - NovoCure Ltd (0001645113) (Filer)
SCHEDULE 13G/A - NovoCure Ltd (0001645113) (Subject)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50
Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00
Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously
H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
H.C. Wainwright downgraded NovoCure from Buy to Neutral and set a new price target of $25.00 from $85.00 previously
Piper Sandler upgraded NovoCure from Neutral to Overweight and set a new price target of $45.00
SVB Securities initiated coverage of NovoCure with a rating of Outperform and set a new price target of $51.00
Evercore ISI upgraded NovoCure from Underperform to In-line and set a new price target of $33.00
Wedbush upgraded NovoCure from Underperform to Neutral and set a new price target of $46.00 from $53.00 previously
Live Leadership Updates
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Novocure (NASDAQ:NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population. "It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer," said Asaf Danziger, Novocure's Chief Executive Officer. "Nicolas brings a wealth
International industry executive Piet Hinoul joins Virtual Incision as chief medical officer, Dmitry Oleynikov transitions to chief surgeon Virtual Incision Corporation, a medical device company developing the world's first miniaturized robotic-assisted surgery (RAS) system, today announced the appointment of global healthcare executive Piet Hinoul, MD, PhD, as chief medical officer (CMO). The company's current CMO Dmitry Oleynikov, MD, FACS will take on the newly established role of chief surgeon, focusing on the research and development of new RAS technology. The expansion of the team strengthens Virtual Incision at a transformative point in its trajectory as it develops new market growt
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
Novocure (NASDAQ:NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure's team members to our anticipated growth. Mr. Burke joined Novocure in 2014 and most recently served as the Senior Vice President of Global Human Resources. He has had extensive experience as a human resources leader for companies such as Arrow Electronics, ThermoFisher Scientific, Novartis Consumer Health, Cadbury Schweppes and PepsiCo. Mr. Burke holds a bachelor's degree in Business and Industrial Relations from the University of Bridgeport, and he has attended management development programs
This live feed shows all institutional transactions in real time.
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
Live finance-specific insights
Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "With the first half of 2025 complete, I am pleased
Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.co
Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen Novocure (NASDAQ:NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive for
Novocure (NASDAQ:NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/investor-
Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S. Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tu
Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Novocure is at an exciting inflection point as we continue to expand our multi-indication TTFields treatment platf
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three-month quarter and first nine months of the year that ended September 30, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations p
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three k
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of